Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeuticsbroad
bioSWITCH · Horizon Europe grant · 2023-03-01–2027-02-28
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2022-PATHFINDEROPEN-01-01. CORDIS record →
Objective
Our vision for a new type of cancer treatment is based on an implantable therapeutic system capable of ‘programmable’ on-demand delivery of drugs directly to the tumor. We conceive an implantable iontronic switch (bioSWITCH) to enable a spatiotemporally controlled administration of highly potent chemotherapeutics, without the need for systemic administration of (pro)drugs or drug conjugates.This radically new technology will be realized by a combination of next-level tools. As a result, bioSWITCH can generate previously unobtainable discrete as well as continuous drug concentration profiles at the tumor site, and thus allows for the use of highly potent drugs that are otherwise not applicable due to high cytotoxicity. The goal is to demonstrate the technology’s potential to effectively interfere with tumor progression using a xenograft pancreas cancer mouse model. Efficiently shrinking tumors in size allows for surgical resection of previously non-operable tumors and dramatically increases survival rates.Our consortium of world leading academics and pioneering SMEs will ensure the translation of this disruptive technology into the market to maximize the socioeconomic impact.
Beneficiaries (7)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| LINKOPINGS UNIVERSITET | SE | coordinator | €1,443,812 | |
| TECHNISCHE UNIVERSITAET WIEN | AT | participant | €735,718 | |
| MEDIZINISCHE UNIVERSITAT GRAZ | AT | participant | €661,026 | |
| SUPRAPOLIX BV | NL | participant | €572,369 | Yes |
| HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT | HU | participant | €449,500 | |
| TAGWORKS PHARMACEUTICALS BV | NL | participant | €447,670 | Yes |
| OBOE IPR AB | SE | participant | €110,416 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.